Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/188964
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pernin, Vincent | - |
dc.contributor.author | Meneghini, Maria | - |
dc.contributor.author | Torija, Alba | - |
dc.contributor.author | Jouve, Thomas | - |
dc.contributor.author | Del Bello, Arnaud | - |
dc.contributor.author | Sanz Muñoz, Iván | - |
dc.contributor.author | Eiros, Jose Maria | - |
dc.contributor.author | Donadeu, Laura | - |
dc.contributor.author | Polo, Carol | - |
dc.contributor.author | Morandeira, Francisco | - |
dc.contributor.author | Navarro, Sergio | - |
dc.contributor.author | Masuet Aumatell, Cristina | - |
dc.contributor.author | Favà Buch, Alexandre | - |
dc.contributor.author | Lequintrec, Moglie | - |
dc.contributor.author | Kamar, Nassim | - |
dc.contributor.author | Crespo, Elena | - |
dc.contributor.author | Bestard Matamoros, Oriol | - |
dc.date.accessioned | 2022-09-12T13:48:08Z | - |
dc.date.available | 2022-09-12T13:48:08Z | - |
dc.date.issued | 2022-07-29 | - |
dc.identifier.issn | 1664-3224 | - |
dc.identifier.uri | http://hdl.handle.net/2445/188964 | - |
dc.description.abstract | Emerging data suggest that costimulation blockade with belatacept effectively controls humoral alloimmune responses. However, whether this effect may be deleterious for protective anti-infectious immunity remains poorly understood. We performed a mechanistic exploratory study in 23 kidney transplant recipients receiving either the calcineurin-inhibitor tacrolimus (Tac, n=14) or belatacept (n=9) evaluating different cellular immune responses after influenza vaccination such as activated T follicular Helper (Tfh), plasmablasts and H1N1 hemagglutinin (HA)-specific memory B cells (HA(+)mBC) by flow-cytometry, and anti-influenza antibodies by hemagglutination inhibition test (HI), at baseline and days 10, 30 and 90 post-vaccination. The proportion of CD4+CD54RA-CXCR5+ Tfh was lower in belatacept than Tac patients at baseline (1.86%[1.25-3.03] vs 4.88%[2.40-8.27], p=0.01) and remained stable post-vaccination. At M3, HA(+)mBc were significantly higher in Tac-treated patients (0.56%[0.32-1.49] vs 0.27%[0.13-0.44], p=0.04) and correlated with activated Tfh numbers. When stratifying patients according to baseline HA(+)mBc frequencies, belatacept patients with low HA(+)mBC displayed significantly lower HA(+)mBc increases after vaccination than Tac patients (1.28[0.94-2.4] vs 2.54[1.73-5.70], p=0.04). Also, belatacept patients displayed significantly lower seroprotection rates against H1N1 at baseline than Tac-treated patients (44.4% vs 84.6%) as well as lower seroconversion rates at days 10, 30 and 90 after vaccination (50% vs 0%, 63.6% vs 0%, and 63.6% vs 0%, respectively). We show the efficacy of belatacept inhibiting T-dependent antigen-specific humoral immune responses, active immunization should be highly encouraged before starting belatacept therapy. | - |
dc.format.extent | 12 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Frontiers Media SA | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3389/fimmu.2022.918887 | - |
dc.relation.ispartof | Frontiers in Immunology, 2022, vol. 13 | - |
dc.relation.uri | https://doi.org/10.3389/fimmu.2022.918887 | - |
dc.rights | cc by (c) Pernin, Vincent et al., 2022 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Virus de la gripe | - |
dc.subject.classification | Trasplantament renal | - |
dc.subject.other | Influenzavirus | - |
dc.subject.other | Kidney transplantation | - |
dc.title | Impaired antigen-specific B-cell responses after Influenza vaccination in kidney transplant recipients receiving co-stimulation blockade with Belatacept | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2022-09-02T09:36:51Z | - |
dc.relation.projectID | info:eu-repo/grantAgreement/EC/H2020/754995/EU//EU-TRAIN | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 35967428 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
fimmu-13-918887.pdf | 5.55 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License